Low-Dose Naltrexone and Finasteride Interaction

Why This Combination Comes Up

Prescriptions for LDN and finasteride increasingly overlap in men between 25 and 55 who use finasteride for androgenetic alopecia or benign prostatic hyperplasia (BPH) while adding LDN for off-label immune or pain conditions. A 2018 systematic review identified over 12,000 patients treated with LDN across published studies for conditions ranging from fibromyalgia to Crohn's disease (1). Finasteride, meanwhile, remains one of only two FDA-approved oral treatments for male-pattern hair loss, with over 3 million annual prescriptions in the United States alone (2).

Neither the FDA label for naltrexone (3) nor the finasteride label (2) lists the other drug as a contraindication or interaction. No dedicated drug-drug interaction (DDI) trial has been conducted pairing these two agents. The clinical reasoning for co-prescribing safety rests on pharmacokinetic and pharmacodynamic first principles, which the sections below examine in detail.

Pharmacokinetic Profile: How Each Drug Is Metabolized

LDN and finasteride travel through the liver by different enzymatic routes, which is the primary reason a meaningful kinetic interaction is unlikely.

Standard-dose naltrexone (50 mg) undergoes extensive first-pass hepatic metabolism. The dominant pathway is reduction by dihydrodiol dehydrogenase (also called aldo-keto reductase 1C) to its major active metabolite, 6-beta-naltrexol (3). CYP enzymes play only a minor secondary role. At LDN doses (1.5 to 4.5 mg), the absolute drug load reaching the liver is roughly 3 to 7% of the approved 50 mg dose, which further reduces any enzyme-level competition.

Finasteride is metabolized primarily by CYP3A4, with a minor CYP3A5 contribution (2). It does not significantly inhibit or induce CYP3A4, CYP2D6, CYP1A2, CYP2C9, or CYP2C19 at therapeutic concentrations (4). Its protein binding is approximately 90%, and its terminal half-life is 5 to 6 hours at the 1 mg dose and 6 to 8 hours at the 5 mg dose.

Because LDN does not rely on CYP3A4 for its primary biotransformation and finasteride does not inhibit the aldo-keto reductase pathway, the two drugs essentially pass through separate metabolic corridors. P-glycoprotein (P-gp) efflux is not a documented transport mechanism for either drug at clinically relevant concentrations, removing another common site of DDI concern.

Pharmacodynamic Assessment: Different Targets, No Receptor Overlap

Pharmacodynamic interactions occur when two drugs act on the same receptor, signaling cascade, or physiological endpoint. That does not apply here.

LDN's proposed mechanism at low doses involves transient opioid-receptor blockade (primarily mu and delta) that triggers a compensatory upregulation of endogenous opioid signaling and modulates Toll-like receptor 4 (TLR4) on microglia (5). A 2014 review in Experimental Biology and Medicine described this TLR4 mechanism as the likely basis for LDN's anti-inflammatory effects in conditions such as fibromyalgia and multiple sclerosis (5). The immunomodulatory action is confined to innate immune signaling and endorphin pathways.

Finasteride is a competitive inhibitor of type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT) (2). At the 1 mg dose, serum DHT drops roughly 70% while testosterone rises modestly within the normal range. The drug has no known activity at opioid receptors, TLR4, or any component of the immune-signaling axis.

There is no shared receptor, enzyme target, or downstream effector pathway between these two drugs. Both may cause mood-related side effects independently (naltrexone at standard doses has been linked to dysphoria; finasteride has post-marketing reports of depression), but this represents overlapping side-effect profiles rather than a true pharmacodynamic interaction. Clinicians should still monitor mood when both are prescribed together, but the mechanism is additive at most, not synergistic.

Liver Safety: The One Area That Warrants Attention

Both LDN and finasteride are hepatically metabolized, and full-dose naltrexone (50 mg) carries an FDA black-box warning for hepatotoxicity at doses of 300 mg/day or higher. That is the single safety consideration worth addressing explicitly.

The black-box warning on the naltrexone label states that hepatocellular injury was observed in clinical trials at five times the approved 50 mg dose (3). At the standard 50 mg dose, clinically significant transaminase elevations are uncommon. At LDN doses (1.5 to 4.5 mg), the hepatic drug burden is a small fraction of even the 50 mg level. A 2020 retrospective cohort study of 215 LDN-treated patients found no cases of hepatotoxicity requiring discontinuation over a median treatment duration of 14 months (6).

Finasteride is considered to have a favorable hepatic safety profile. Post-marketing hepatotoxicity reports exist but are rare, and the LiverTox database maintained by the National Institute of Diabetes and Digestive and Kidney Diseases classifies finasteride-related liver injury as uncommon (7).

A reasonable monitoring framework for patients on both agents: obtain baseline ALT and AST before starting the combination, repeat at 3 months, and then annually if values remain within the normal range. Patients with pre-existing hepatic impairment (Child-Pugh class B or C) should have more frequent surveillance, and LDN initiation in this population should begin at 1.5 mg with slow titration.

Dose-Adjustment Recommendations

No dose adjustment of either LDN or finasteride is required when the two are co-prescribed in patients with normal hepatic and renal function.

For LDN, the standard titration protocol begins at 1.5 mg nightly for 1 to 2 weeks, increasing to 3 mg for another 1 to 2 weeks, then to 4.5 mg as tolerated (1). This protocol does not need modification because of finasteride. For finasteride, the approved dose is 1 mg daily for androgenetic alopecia or 5 mg daily for BPH, and these do not need to change because of LDN.

In patients with moderate renal impairment (eGFR 30 to 59 mL/min), naltrexone clearance may decrease. A dose reduction to 1.5 to 3 mg of LDN may be appropriate in this population regardless of finasteride use. Finasteride does not require renal dose adjustment.

Clinical Monitoring Protocol

Monitoring for this combination is straightforward because the interaction risk is low. The following schedule consolidates standard-of-care monitoring for each drug individually.

At baseline (before starting both drugs together): complete metabolic panel including ALT, AST, and total bilirubin; serum creatinine and eGFR; PSA if finasteride is prescribed for BPH (finasteride lowers PSA by approximately 50%, so a baseline value must be recorded before initiation) (2); mood and mental-health screening using a validated tool such as the PHQ-9.

At 3 months: repeat ALT and AST; mood reassessment; evaluation of treatment response for both conditions.

At 6 and 12 months, then annually: liver enzymes if the baseline was normal and no symptoms have emerged; PSA if applicable (remembering to double the reported value to estimate the true level while on finasteride); continued mood monitoring.

Patients should be counseled to report symptoms of hepatic dysfunction (right upper quadrant pain, dark urine, jaundice, unexplained fatigue) and to report new or worsening depressive symptoms promptly.

What the DDI Databases Say

A search of the three most commonly used drug-interaction databases yields consistent results for this pair.

Lexicomp, Micromedex, and Epocrates do not list a specific interaction between naltrexone (at any dose) and finasteride. The Drugs.com interaction checker similarly returns no result for this combination. The absence of a listing in these databases does not prove safety with absolute certainty, but it reflects the pharmacologic expectation that two drugs with separate metabolic pathways and unrelated mechanisms of action present negligible interaction risk.

The Endocrine Society's 2019 clinical practice guideline on androgen therapy in women references finasteride's CYP3A4 metabolism but does not identify naltrexone as a concern (8). The American College of Gastroenterology's 2018 guidelines on the use of naltrexone for alcohol use disorder discuss hepatic monitoring but do not flag any 5-alpha reductase inhibitor interaction (9).

Special Populations

Certain patient groups merit additional consideration, not because the interaction becomes dangerous, but because the individual drug profiles each carry population-specific concerns.

Women of reproductive age: Finasteride is FDA pregnancy category X. Women who are or may become pregnant must not handle crushed or broken finasteride tablets due to the risk of feminization of a male fetus (2). LDN used off-label in women with autoimmune conditions does not change this contraindication.

Patients on opioid therapy: LDN, even at 1.5 to 4.5 mg, can precipitate opioid withdrawal in patients taking opioid analgesics (3). This is unrelated to finasteride but must be screened for before any LDN initiation. A minimum 7 to 10 day washout from short-acting opioids (or 10 to 14 days from long-acting formulations) is the standard recommendation before starting LDN.

Older adults with BPH: Men over 65 on finasteride 5 mg may have slightly reduced hepatic blood flow. While this does not create a meaningful interaction with LDN, the general principle of starting LDN at 1.5 mg and titrating slowly applies. PSA monitoring is mandatory in this group per AUA/ASCO guidelines, and the clinician must account for finasteride's PSA-lowering effect to avoid missing a prostate cancer diagnosis.

The Mood Side-Effect Overlap

Both drugs have independent associations with mood changes, so this overlap deserves direct discussion even though it is not a true drug interaction.

Finasteride's FDA label notes post-marketing reports of depression, and a 2020 meta-analysis of 6 studies (N = 2,413 men) found a statistically significant but small increase in depressive symptoms among finasteride users compared to placebo (OR 1.47, 95% CI 1.04 to 2.08) (10). Standard-dose naltrexone (50 mg) has listed dysphoria and anxiety as adverse effects in approximately 3 to 10% of patients in clinical trials (3). Whether these mood effects occur at LDN doses is less established; a 2022 pilot study of LDN 4.5 mg in 36 fibromyalgia patients did not find a significant increase in depressive symptoms versus placebo over 12 weeks (11).

The practical takeaway: if a patient on this combination reports new mood symptoms, consider each drug individually as a potential contributor rather than assuming a drug interaction.

Patient Counseling Points

Prescribers and pharmacists should cover five specific topics when a patient picks up both medications together.

First, timing. LDN is typically taken at bedtime because it can cause vivid dreams or mild sleep disruption. Finasteride has no time-of-day preference. Taking LDN at night and finasteride in the morning provides maximal separation of peak plasma levels, though this is a convenience strategy, not a safety requirement.

Second, alcohol. LDN's parent compound naltrexone is FDA-approved to reduce alcohol cravings. Even at low doses, patients should know that LDN may blunt the subjective effects of alcohol. Finasteride has no direct alcohol interaction.

Third, pregnancy exposure. Any female partner of a male patient on finasteride should avoid contact with crushed tablets. LDN does not change this risk, but it is a key counseling point for the combination.

Fourth, lab work. Explain the rationale for periodic liver-function testing. Most patients appreciate understanding that this is precautionary rather than indicative of a known problem.

Fifth, opioid avoidance. Patients must inform all healthcare providers (including emergency departments) that they are on LDN before any opioid is prescribed. LDN's blockade of the mu-opioid receptor, even at low doses, may reduce opioid analgesic efficacy and could precipitate withdrawal in opioid-dependent individuals.